Cyclosporin a formulations as nanoparticles

Details Cyclosporin a formulations as nanoparticles Cyclosporin a formulations as nanoparticles

1996-03-25

1998-10-27

Russel, Jeffrey E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514938, A61K 910, A61K 3813

Patent

active

058278222

ABSTRACT:
Cyclosporin A formulations are provided as amorphous nanoparticle dispersions for physiologic absorption. The compositions have high bioavailability and patient acceptability. By providing for concentrates comprising lower alkanols and a polyoxyalkylene surfactant as a stable dispersion of cyclosporin A, upon introducing the stable dispersion into an aqueous medium, the subject formulation is produced comprising amorphous bioavailable cyclosporin nanoparticles.

REFERENCES:
patent: 4117118 (1978-09-01), Harri et al.
patent: 4220641 (1980-09-01), Traber et al.
patent: 4388307 (1983-06-01), Cavanak
patent: 4792449 (1988-12-01), Ausman et al.
patent: 4889723 (1989-12-01), Kim et al.
patent: 4970076 (1990-11-01), Horrobin
patent: 4990337 (1991-02-01), Kurihara et al.
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5047396 (1991-09-01), Orban et al.
patent: 5051402 (1991-09-01), Kurihara et al.
patent: 5118493 (1992-06-01), Kelley et al.
patent: 5154930 (1992-10-01), Popescu et al.
patent: 5206219 (1993-04-01), Desai
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5350741 (1994-09-01), Takada
patent: 5364632 (1994-11-01), Benita et al.
patent: 5389382 (1995-02-01), List et al.
patent: 5474979 (1995-12-01), Ding et al.
patent: 5504068 (1996-04-01), Komiya et al.
patent: 5540931 (1996-07-01), Hewitt et al.
patent: 5583105 (1996-12-01), Kovacs et al.
patent: 5614491 (1997-03-01), Walch et al.
Tarr et al. "Enhanced Intestinal Absorption of Cyclosporine in Rats Through the Reduction of Emulsion Droplet Size." Pharm. Res. vol. 6, pp. 40-43, 1989.
Abdallah et al. "The Preparation and Evaluation of a Tablet Dosage Form of Cyclosporine in Dogs." Pharm. Res. vol. 8, pp. 518-522, 1991.
Sato et al. "Enhancement of The Intestinal Absorption of Cyclosporine Derivative by Milk Fat Globule Membrane." Biol. Pharm. Bull. vol. 17, pp. 1526-1528, 1994.
Benmoussa et al. "Cyclosporin Absorption Is Impaired by the Fat Substitutes, Sucrose Polyester and Tricarballylate Triester, in the Rat." Pharm. Res. vol. 11, pp. 1458-1461, 1994.
Trull et al. "Cyclosporin Absorption From Microemulsion Formulation in Liver Transplant Recipient." The Lancet. vol. 341, p. 433, 1993.
Ferrea et al. "Oral Microemulsion Formulation Substitutes for Intravenous Cyclosporin in Child with Graft-Versus-Host Disease." The Lancet. vol. 344, pp. 480-481, 1994.
Reymond et al. "In Vivo Model for Ciclosporin Intestinal Absorption in Lipid Vehicles." Pharm. Res. vol. 5, pp. 677-679, 1988.
Ritschel et al. "Improvement of Peroral Absorption of Cyclosporine A By Microemulsions." Meth. Find Exp. Clin. Pharmacol. vol. 12, pp. 127-134, 1990.
Reymond et al. "In Vitro Model for Ciclosporin Intestinal Absorption in Lipid Vehicles." Pharm. Res. vol. 5, pp. 673-676, 1988.
Cavanak et al. "Formulation of Dosage Forms." Prog. Allergy. vol. 38, pp. 65-72, 1986.

Affiliated with

Also associated with

Rating

Cyclosporin a formulations as nanoparticles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclosporin a formulations as nanoparticles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclosporin a formulations as nanoparticles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1613864